Panbela opens enrollment in uk and germany for aspire trial in pancreatic cancer, all countries/regions in the aspire trial are now open and actively enrolling

Minneapolis, july 24, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has opened enrollment in the uk and germany for its aspire global clinical trial in the first-line treatment of metastatic pancreatic cancer. aspire is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
PBLA Ratings Summary
PBLA Quant Ranking